möglich sobald bei der ZB eingereicht worden ist.
Regenerative medicine and the hope for a cure.
Clin. Chest Med. 42, 365-373 (2021)
Current therapeutic strategies have succeeded in slowing down the progression of idiopathic pulmonary fibrosis (IPF). Emerging evidence highlights IPF as a disease of aging and impaired regeneration. Novel antiaging and regenerative medicine approaches hold promise to be able to reverse disease and might present hope for a cure. Research focusing on a deeper understanding of lung stem cell populations and how these are regulated and altered in fibrotic disease continues to drive the field, and accompanied by earlier diagnosis, the adaptation of clinically relevant models and readouts for regeneration of diseased lung, ultimately paves the way for translation into clinics.
Impact Factor
Scopus SNIP
Altmetric
2.878
1.773
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Review
Schlagwörter
Aging ; Cellular Senescence ; Developmental Pathways ; Ild ; Ipf ; Regeneration ; Translation; Idiopathic Pulmonary-fibrosis; Cellular Senescence; Lung Development; Stem-cells; Alveolar Progenitor; Aging Lung; Wnt; Mechanisms; Repair; Tgf
Sprache
englisch
Veröffentlichungsjahr
2021
HGF-Berichtsjahr
2021
ISSN (print) / ISBN
0272-5231
e-ISSN
1557-8216
Zeitschrift
Clinics in chest medicine
Quellenangaben
Band: 42,
Heft: 2,
Seiten: 365-373
Verlag
Elsevier
Verlagsort
1600 John F Kennedy Boulevard, Ste 1800, Philadelphia, Pa 19103-2899 Usa
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Lung Health and Immunity (LHI)
POF Topic(s)
30202 - Environmental Health
80000 - German Center for Lung Research
80000 - German Center for Lung Research
Forschungsfeld(er)
Lung Research
PSP-Element(e)
G-503100-001
G-501800-311
G-501800-311
WOS ID
WOS:000653200800014
PubMed ID
34024411
Erfassungsdatum
2021-06-28